Tivic Health Systems (TIVC) shares soared 220% in Tuesday's premarket after it said discussions with the White House drew "significant positive interest" for potential defense applications for its biologic and bioelectronic product candidates.
The therapeutics company also said it met with the Food and Drug Administration to discuss ways to expedite approval of Entolimod and Entolasta. Entolimod, the firm's lead drug candidate is intended to treat neutropenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.